This 1 Company May Still Be the Best Contrarian Play of the Year

Here’s why Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may still be one of the best contrarian plays for 2017.

| More on:

In October of last year, I wrote about why I thought Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may be the best contrarian play for 2017; since then, a lot has happened.

I thought I would revisit the Valeant turnaround thesis once more, this time with the emphasis on the pharmaceutical company’s management team — a management team I believe has done an amazing job of creating value for shareholders over the course of the past six to 12 months.

Investors want to know what they are going to get

Uncertainty is a terrible thing in general; I want to know what is for dinner, how long I will have to wait in line for that new movie everyone wants to see, and, overall, what my rate of return will be on a given investment.

With Valeant, trying to gauge what my return on investment will be this year or next year may be extremely difficult; however, what has become clear in management’s execution of its strategic plan is that I will be able to gauge with some certainty where the company is going and how the company intends to get there.

The ability of any management team to do what they say they are going to do should not be undervalued. In my opinion, part of the recent (deserved) rise in the value of Valeant stock can be attributed to investors simply giving the company’s management props for getting the business to where it is today in terms of debt reduction and a return to a reasonable path to long-term profitability.

Divestitures can support a return to organic growth

The company’s latest divestiture of its iNova Pharmaceuticals business for nearly $1 billion in cash is yet another in a long list of steps the company has made to move toward its goal of paying down $5 billion of debt by early 2018. Valeant remains a significant player in terms of its drug portfolio, and while its R&D program isn’t what it once was (due to a shift toward an infamous and ineffective buy-and-hike acquisition program), the company has a decent pipeline of drugs as well a number of valuable pieces it can still sell off to focus on returning to its “organic” growth roots.

Following a divestiture plan strictly can be a difficult thing to do (obviously, the company’s best drugs will be the first ones potential suitors call about); however, at this point in time, with the company’s stock price hit so hard of late, raising capital via an equity issuance just doesn’t make as much sense as biting the bullet and repaying debt as quickly as possible.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A data center engineer works on a laptop at a server farm.
Tech Stocks

3 No-Brainer Data Centre Stocks to Buy With $500 Right Now

Data centres are going to be a huge growth opportunity in the next decade. And these are the top buys.

Read more »

Paper Canadian currency of various denominations
Bank Stocks

1 Magnificent Canadian Dividend Stock Down 28% to Buy and Hold for Decades

This top Canadian dividend stock is underperforming its large peers this year, but a turnaround could be on the horizon.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

Where to Invest Your $7,000 TFSA Contribution

The TFSA is attractive for investors who want to generate tax-free passive income.

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Dividend Stocks

TFSA Investors: 3 Dividend Stocks Worth Holding Forever

These TSX stocks have the potential to grow their dividends over the next decade, making them top investments for TFSA…

Read more »

hand stacks coins
Investing

Secure a Wealthy Future With These 3 Canadian Stocks

These Canadian stocks have the potential to appreciate substantially over time and may also enhance returns through dividend payments.

Read more »

Tractor spraying a field of wheat
Dividend Stocks

Is Nutrien Stock a Buy for its Dividend Yield?

Nutrien is down more than 50% form the 2022 highs. Is NTR stock now oversold?

Read more »

analyze data
Investing

3 Blue-Chip Stocks Every Canadian Should Own

These blue-chip stocks are backed by large-cap companies with well-established businesses, solid fundamentals, and a growing earnings base.

Read more »

dividends grow over time
Stocks for Beginners

The Smartest Growth Stock to Buy With $2,000 Right Now

Do you have $2,000 to invest for the long term? These three TSX stocks have and will continue to deliver…

Read more »